Interview Airs June 17, 2015, Host Geraldo Rivera, 10:52 AM ET | 9:52 AM CT | 7:52 AM PT

ALACHUA, Fla., June 17, 2015 (GLOBE NEWSWIRE) — via PRWEB – AxoGen, Inc. (AXGN), leading medical technology company focused on restoring quality of life through nerve repair, announced today that Chief Executive Officer Karen Zaderej will be interviewed in a special three-day Q&A miniseries on the “Geraldo Rivera Show,” hosted by Geraldo Rivera and broadcasted on 77 WABC from New York City. In the second installment of this three-part interview, Ms. Zaderej dives into the common symptoms of nerve injuries including pain, loss of sensation and lack of movement and the use of AxoGen’s portfolio of nerve repair products in procedures to help patients. Ms. Zaderej will also discuss the importance of a timely diagnosis by a peripheral nerve specialist.

All shareholders, analysts, industry professionals, health care providers and anyone experiencing symptoms of a nerve injury are encouraged to listen to the broadcast to learn more about options in nerve repair. Broadcast details for the second of three segments are as follows:

Date: Wednesday, June 17, 2015
Start Time: 10:52 AM ET | 9:52 AM CT | 7:52 AM PT
Network: WABC
Station: 770 AM, 77WABC Radio
Show: “Geraldo Rivera Show”
Host:Geraldo Rivera

About Geraldo Rivera

Geraldo Rivera: A three-time recipient of the 2000 Robert F. Kennedy journalism award. He has received more than 170 awards for journalism, including the prestigious George Foster Peabody Award, three national and seven local Emmys, two Columbia-Dupont and two additional Scripps Howard Journalism Awards. Rivera is a graduate of the University of Arizona and Brooklyn Law School and is the author of seven books.
http://www.geraldo.com/ | http://www.wabcradio.com/geraldorivera/

About AxoGen, Inc.

AxoGen (AXGN) is a leading medical technology company dedicated to peripheral nerve repair. AxoGen’s portfolio of regenerative medicine products is available in the United States, Canada and several other countries and includes Avance(R) Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard(R) Nerve Connector, a porcine submucosa extracellular matrix (“ECM”) coaptation aid for tensionless repair of severed nerves, and AxoGuard(R) Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

To learn more about AxoGen and to sign up for news alerts, visit http://www.AxoGenInc.com.

Cautionary Statement Concerning Forward-Looking Statements

This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding our growth, our product development and product potential. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and, except as required by law, AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.